tbuckley/cabot-search huggingface dataset:
The association of sleep disturbances measures with blood pressure: is the time to explore novel measurements?
Authors: Bharati Prasad, Manuel Sánchez-de-la-Torre
Journal: Thorax (2019)

<b>Introduction:</b> Pirfenidone is a currently available therapy in IPF, however there is insufficient real-life data on its efficacy. <b>Aims and Objectives:</b> Evaluation of efficacy of Pirfenidone in IPF in a real life setting. <b>Methods:</b> Observational, real-life study of Pirfenidone in IPF. <b>Results:</b> 49, out of 58 patients initially treated, (38 male), mean age at diagnosis 70.39±7.14 years were analysed. Patients were followed before initiation of therapy for a median duration of 6 (3-120) months. At Pirfenidone introduction they presented mild/moderate disease (mean FVC=72.51%±14.09% and TLCO<sub>SB</sub>=45.18±14.94% of predicted) and were classified according to the GAP index as class Ι=1 patient, ΙΙ=11, ΙΙΙ=31 and IV=6. Concomitant emphysema (CPFE) was present in 31% and RVSP&gt;35mmHg (mean=48.82±11.22mmHg) in 37% of the patients examined. Patients received Pirfenidone for a median duration of 21 (6-36) months, with an average daily dose of 2203 mg. Analysis of functional outcomes at 12, 24 and 36 months since initiation of therapy was performed and changes in FVC% and TLCO<sub>SB</sub>% were -2.20±5.62% and -3.67±7.10%, -7.61±6.29% and -12.36±10.56% and -7.87±7.10% and -11.40±16.12%, respectively. FVC% and TLCO<sub>SB</sub>% rate of decline at 12 months before and after initiation of therapy was studied in patients with available data with no significant differences found in the whole population, however subgroup analysis showed significant reductions in the rate of TLCO<sub>SB</sub>% decline for GAP stage III and CPFE patients by 17.39% (p=0.047) and 13.33% (p=0.015), respectively. <b>Conclusions:</b> Patients on Pirfenidone did not show significant deterioration during their follow up and therapy retarded the rate of TLCO<sub>SB</sub>% decline in certain subgroups.
Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival
Authors: Dipenkumar Modi, Seongho Kim, Jie Chi, Lois Ayash, Asif Alavi, Andrew Kin, Voravit Ratanatharathorn, Joseph P. Uberti, Abhinav Deol
Journal: Blood (2019)
Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Authors: Shannon R. McCurdy, Shannon H. Gier, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Alexander E. Perl, Ivan Maillard, Keith W. Pratz, David L. Porter, Martin P. Carroll, Phyllis A. Gimotty, Selina M. Luger
Journal: Blood (2019)
Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response
Authors: Mahnaz Sahraei, Balkrishna Chaube, Yuting Liu, Jonathan Sun, Alanna Kaplan, Nathan L. Price, Wen Ding, Stanley Oyaghire, Rolando García-Milian, Sameet Mehta, Yana K. Reshetnyak, Raman Bahal, Paolo Fiorina, Peter M. Glazer, David L. Rimm, Carlos Fernández-Hernando, Yajaira Suárez
Journal: Journal of Clinical Investigation (2019)

microRNA-21 (miR-21) is the most commonly upregulated miRNA in solid tumors. This cancer-associated microRNA (oncomiR) regulates various downstream effectors associated with tumor pathogenesis during all stages of carcinogenesis. In this study, we analyzed the function of miR-21 in noncancer cells of the tumor microenvironment to further evaluate its contribution to tumor progression. We report that the expression of miR-21 in cells of the tumor immune infiltrate, and in particular in macrophages, was responsible for promoting tumor growth. Absence of miR-21 expression in tumor- associated macrophages (TAMs), caused a global rewiring of their transcriptional regulatory network that was skewed toward a proinflammatory angiostatic phenotype. This promoted an antitumoral immune response characterized by a macrophage-mediated improvement of cytotoxic T-cell responses through the induction of cytokines and chemokines, including IL-12 and C-X-C motif chemokine 10. These effects translated to a reduction in tumor neovascularization and an induction of tumor cell death that led to decreased tumor growth. Additionally, using the carrier peptide pH (low) insertion peptide, we were able to target miR-21 in TAMs, which decreased tumor growth even under conditions where miR-21 expression was deficient in cancer cells. Consequently, miR-21 inhibition in TAMs induced an angiostatic and immunostimulatory activation with potential therapeutic implications.
Affect of Age on Survival and Complications after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major
Authors: Yiqi Xu, Yongsheng Ruan, Yuelin He, Jianyun Wen, Xiaoqin Feng, Xuan Liu, Haixia Guo, Chunfu Li, Qareen Haque, Xuedong Wu
Journal: Blood (2019)
Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Authors: Roy Chemaly, Michael Boeckh, Karin Weber, Roman Fleischhackl, Marita Stevens, Bart Michiels, David Rivas, Jason Chien, James Witek
Journal: Blood (2019)
RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression
Authors: Monika Hruba, Jitka Vesela, Hana Votavova, Michaela Dostalova Merkerova, David Kundrat, Katarina Szikszai, Marie Lauermanova, Zuzana Zemanova, Anna Jonasova, Jaroslav Cermak, Monika Belickova
Journal: Blood (2019)
Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study
Authors: Neil L Berinstein, Isabelle Bence-Bruckler, Pierre Laneuville, Douglas A. Stewart, Nicholas Allen Forward, Liam Smyth, Gail Klein, Nancy Pennell, Kim Roos
Journal: Blood (2019)
PATH-41. LONGITUDINAL MATCHED MUTATIONAL ANALYSIS IN RECURRENT AND MULTIFOCAL GLIOMAS
Authors: Ahmad Daher
Journal: Neuro-Oncology (2019)

Abstract Re-resection of recurrent gliomas and multifocal gliomas are relatively uncommon resulting in limited understanding of the molecular profile of gliomas in those settings. Here we present a comprehensive mutational analysis via next generation sequencing (NGS) of 20 gliomas from 9 patients treated at our institution: one recurrent oligodendroglioma, one secondary glioblastoma (GBM), five locally recurrent primary GBMs, and two multifocal recurrent primary GBMs. Tumor mutational burden (TMB) range was 1.8–60.6 mutations/megabase (mt/Mb). Elevated TMB was seen in the initial (49.2 mt/Mb) and recurrent (60.6 mt/Mb) secondary GBM samples and in the distal recurrent GBM sample (50.9 mt/Mb) of one of the two patients with multifocal recurrent disease, suggesting a temozolomide-induced hypermutated state. Interestingly, the elevated TMB in the patient of multifocal recurrence occurred 5 years after completing 12 cycles of TMZ and was seen in the distal but not local focus of disease recurrence where TMB remained at 1.8 mt/Mb. The patient with multifocal (right frontal and right temporal) GBM at diagnosis developed recurrence in the temporal location only. NGS of the 2 resected tumors revealed 4 common somatic mutations, 3 mutations unique to the right frontal lesion and 8 mutations unique to the right temporal lesion. Additionally, our oligodendroglioma who was heavily treated in the six years prior to his last recurrence retained 4/6 of the initial somatic mutations and acquired 5 new ones upon the last recurrence. This analysis further highlights glioma spatiotemporal heterogeneity and the linear and divergent evolution upon disease recurrence and in the multifocal pre-treatment and recurrent settings. We also show that extensive oncogenic alterations can occur upon glioma recurrence, which is a major therapeutic barrier in managing recurrent disease, a barrier that can render the initial genomic profile of the disease, the basis of molecularly targeted therapy in the majority of cases, less meaningful.
Deciphering Molecular Heterogeneity in Pediatric AML Using a Cancer Vs Normal Transcriptomic Approach
Authors: Barbara Depreter, Mattias Hofmans, Eva Terras, Anne Uyttebroeck, An Van Damme, Alina Ferster, Jutte Van der Werff Ten Bosch, Marie-Françoise Dresse, Karl Vandepoele, Barbara De Moerloose, Jan Philippé, Tim Lammens
Journal: Blood (2019)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Authors: Irene M. Ghobrial, Chia-Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael D. Robbins, Pamela S. Becker
Journal: Clinical Cancer Research (2019)

Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.This phase Ib/II study aimed to determine the safety and tolerability of ulocuplumab alone and in combination with lenalidomide and dexamethasone (Arm A), or bortezomib and dexamethasone (Arm B), in patients with relapsed/refractory multiple myeloma.Forty-six patients were evaluated (median age, 60 years; range, 53-67). The median number of prior therapies was 3 (range, 1-11), with 70% of subjects having received ≥3. This trial had a dose-escalation and a dose-expansion part. Using a 3+3 design on both arms of the trial, ulocuplumab's dose was escalated to a maximum of 10 mg/kg without reaching MTD. The most common treatment-related adverse events (AE) were neutropenia (13 patients, 43.3%) in Arm A and thrombocytopenia (6 patients, 37.5%) in Arm B. No deaths related to study drugs occurred. The combination of ulocuplumab with lenalidomide and dexamethasone showed a high response rate (PR or better) of 55.2% and a clinical benefit rate of 72.4%, even in patients who had been previously treated with immunomodulatory agents (IMiD).This study showed that blockade of the CXCR4-CXCL12 axis by ulocuplumab is safe with acceptable AEs and leads to a high response rate in combination with lenalidomide and dexamethasone in patients with relapsed/refractory myeloma, making CXCR4 inhibitors a promising class of antimyeloma drugs that should be further explored in clinical trials.
The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease
Authors: Minke A.E. Rab, Richard van Wijk, Celeste K. Kanne, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, Jorn J. Gerritsma, Karin Fijnvandraat, Celine Renoux, Marije Bartels, Erfan Nur, Marjon H. Cnossen, Philippe Joly, Romain Fort, Philippe Connes, Eduard J. van Beers, Vivien A. Sheehan
Journal: Blood (2019)
Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients
Authors: Haruya Okamoto, Akihiro Miyashita, Hiroaki Nagata, Yasuhiko Tsutsumi, Yuri Kamitsuji, Yutaka Kobayashi, Nobuhiko Uoshima
Journal: Blood (2019)
SURG-02. STAGED SURGERY FOR SELECTED GIANT ADULT PITUITARY ADENOMA
Authors: Jun Ma, Shunchang Ma, Guijun Jia, Fei Yao, Wang Jia
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Combined surgical strategy with both trans-cranial surgery and trans-sphenoid surgery is necessary for selected giant pituitary adenoma with both intra-cranial and intra-sphenoidal invasion. Cases of staged surgery were reviewed retrospectively to deeply investigate this treatment strategy. METHODS Adult cases received staged surgery were reviewed. Data regarding clinical presentation, laboratory tests, image examination, surgery details, and outcome were analyzed. The size and invasion was evaluated by pre-op MR and intra-op observation. Diagnosis was confirmed by histology examination. Literatures were reviewed. RESULTS 8 NFPAs were included. 4 received trans-cranial resection first while the other 4 received trans-sphenoidal resection first. Time interval between two operations was 1–2 months. After the first surgery, the rate of visual defects and of pituitary hypofunction improvement were higher in trans-cranial first group. 1 apoplexy and 1 CSF rhinorrhea were observed in trans-sphenoidal first group. After the second surgery, the extend of resection and the rate of complete visual symptoms improvement were higher in trans-cranial first group. All pituitary hypofunction resolved completely in long-term follow-up. 11 literatures were reviewed. CONCLUSIONS An appropriate surgical strategy is essential for selective pituitary adenoma requiring combined resection. For staged surgery cases, taking trans-cranial approach for first stage with trans-sphenoidal subsequently, comparing to the inverse resection order, would offer higher extent of resection with less recurrence, earlier and better symptom improvement, and less post-op complications after first stage. Further investigation is necessary.
Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
Authors: Seth M Maliske, Matthew J. Maurer, Carrie A. Thompson, Luis Porrata, Ivana Micallef, Rebecca L. King, Sergei Syrbu, Brian K. Link, Margarida Magalhaes Silverman, Yogesh Jethava, David James J Inwards, Stephen M Ansell, James R. Cerhan, Patrick Johnston, Umar Farooq
Journal: Blood (2019)
NIMG-51. THE CENTRALLY RESTRICTED DIFFUSION SIGN FOR DIFFERENTIATION BETWEEN TREATMENT-RELATED LESIONS AND TUMOR PROGRESSION IN GLIOMA PATIENTS: A VALIDATION STUDY
Authors: Paula Alcaide-Leon, Julia Cluceru, Tracy Luks, Janine Lupo, Javier Villanueva-Meyer
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The aim of the study was to compare the diagnostic accuracy of different diffusion patterns for differentiation between treatment-related lesions and true tumor progression in patients with suspected glioma recurrence. METHODS A retrospective analysis of a prospective cohort was conducted. The images of 240 consecutive patients who underwent surgery for suspected glioma recurrence were reviewed for potential inclusion. Exclusion criteria were lack of a ring-enhancing lesion and presence of susceptibility artifact. Final diagnosis was established upon review of histopathology reports. Lesions showing treatment-related changes and less than 25% of viable tumor were considered treatment-related lesions. More than 25% of viable tumor was considered recurrent tumor. A neuroradiologist, blinded to the diagnosis, evaluated the diffusion patterns on preoperative MRI. ROC curve analysis was performed. RESULTS One hundred and ten patients were included (26 with treatment-related lesions and 84 with tumor progression). Of 110, 35 showed no reduced diffusion. Fifty patients had reduced diffusion in the solid lesion component (84%, recurrent tumor and 16%, treatment-related lesions). Twenty-five patients showed reduced diffusion within the central necrosis (48%, recurrent tumor and 52%, treatment-related lesions). Most cases with reduced diffusion in the central necrotic region showed mixed pathology with concurrent treatment effect and viable tumor. The AUC for the combined diffusion pattern (reduced diffusion in the solid lesion component vs in the necrotic region) was 0.68 (95%CI=0.55–0.81). The AUC for the traditional diffusion approach (reduced diffusion in the solid lesion component vs no reduced diffusion) was 0.59 (95%CI=0.49–070). No significant differences were found in AUC (p=0.3). CONCLUSION Although the existence of centrally reduced diffusion seems to be associated with the presence of treatment effect, it does not significantly increase the diagnostic accuracy of the traditional diffusion evaluation approach. This is most likely related to the high incidence of concurrent recurrent tumor and treatment effect.
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Authors: Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon E. Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Jason A. Dubovsky, Julie Rytlewski, Lin Yang, William G. Wierda
Journal: Blood (2019)
Is Arterial Puncture Dangerous?
Authors: M. M. Platts, B. A. Ridgway
Journal: BMJ (1965)

of cancer in a cell (of the system under study) is G(t) and that there are n cells " at risk."On the usual independence assumption we may then deduce the probability distri- bution function of age of appearance of the disease in the individual as3 4The age-specific incidence of the disease at age t will then be f(t)/ {1 -F(t)}, where f(t) = dF(t)/dt.For large n, F(t) will be virtually determined by the structure of G(t) as G(t)->O.3This can be shown to imply that any g(t)[ =dG(t)/dt] which behaves as a power of t for small G(t) will produce the known age-specific incidence pattern.3For example, both the following g(t)'s will produce the required age-specific incidence pattern:(I) g(t) =e-At Ar tr-1/(r-l)!(2)(1) is the model of r somatic mutations re- quired in any order within a single cell where the mutations occur at a constant rate A per cell per year, and (2) is the well-known F distribution on vi and V2 degrees of freedom.We carry no torch for any particular alter- native theory but wish only to point out that no theory of carcinogenesis can be considered to be established solely on the basis of the mathematical relationship between incidence rates and age.-Weare, etc.,
Pathologie und Klinik in Einzeldarstellungen.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fostering Resilience Among Youths Exposed to Adverse Childhood Experiences—Reply
Authors: Molly C. Easterlin, Paul J. Chung, Rebecca Dudovitz
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Polymorphisms in Inflammatory Genes Modulate the Occurrence of Clinical Complications in Patients with Sickle Cell Disease
Authors: Karina Tozatto-Maio, Robert Girot, Indou Deme Ly, Vanderson Rocha, Ana Cristina Silva Pinto, Ibrahima Diagne, Yahia Benzerara, Francisco Fernandes, Carla Luana Dinardo, Simone Kashima, Itaua Leston Araujo, Chantal Kenzey, Guilherme Henrique Hencklain Fonseca, Evandra Strazza Rodrigues, Fernanda Volt, Luciana Ribeiro Jarduli, Annalisa Ruggeri, Christina Mary Mariaselvam, Sandra Fatima Menosi Gualandro, Hanadi Elayoubi, Renato Cunha, Barbara Cappelli, Julia Pavan, Belinda Pinto Simões, Eliane Gluckman, Ryad Tamouza
Journal: Blood (2019)
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Authors: R. Alejandro Sica, Michael A Spinner, John S Tamaresis, Ranjana H Advani, Laura J Johnston, Robert Lowsky, Everett H Meyer, David B Miklos, Lori S Muffly, Andrew R Rezvani, Judith A Shizuru, Wen-Kai Weng, Robert S. Negrin, Sally Arai
Journal: Blood (2019)
Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)
Authors: Tiziana Vaisitti, Katti Jessen, Thanh-Trang Vo, Mira Ko, Francesca Arruga, Nicoletta Vitale, Esteban Braggio, Arianna Di Napoli, Amy Chadburn, John N. Allan, Richard R. Furman, Langdon L. Miller, Brian J Lanutti, Silvia Deaglio
Journal: Blood (2019)
Restoring Functional Deficits in Older Adults with Hematologic Malignancy
Authors: Ashley E. Rosko, Sarah A Wall, Robert A Baiocchi, Don M. Benson, Jonathan E. Brammer, John C. Byrd, Yvonne A. Efebera, Kami J. Maddocks, Kerry A. Rogers, Carolyn Presley, Desiree Jones, Ying Huang, Michelle Naughton
Journal: Blood (2019)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Authors: Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda J. Gooderham, Lisa A. Beck, Emma Guttman-Yassky, David Pariser, Andrew Blauvelt, Jamie Weisman, Benjamin Lockshin, Thomas Hultsch, Qin Zhang, Mohamed A. Kamal, John D. Davis, Bolanle Akinlade, Heribert Staudinger, Jennifer D. Hamilton, Neil M. H. Graham, Gianluca Pirozzi, Abhijit Gadkari, Laurent Eckert, Neil Stahl, George D. Yancopoulos, Marcella Ruddy, Ashish Bansal
Journal: JAMA Dermatology (2019)

Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population.